Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Activation of the proapoptotic receptor death receptor5 (DR5) in various cancer cells triggers programmed cell death through the extrinsic pathway. We have generated a fully human monoclonal antibody (Apomab) that induces tumor cell apoptosis through DR5 and investigated the structural features of its interaction with DR5. Biochemical studies showed that Apomab binds DR5 tightly and selectively. X-ray crystallographic analysis of the complex between the Apomab Fab fragment and the DR5 ectodomain revealed an interaction epitope that partially overlaps with both regions of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand binding site. Apomab induced DR5 clustering at the cell surface and stimulated a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Apomab's proapoptotic activity. In vitro, Apomab triggered apoptosis in cancer cells, while sparing normal hepatocytes even upon anti-Fc crosslinking. In vivo, Apomab exerted potent antitumor activity as a single agent or in combination with chemotherapy in xenograft models, including those based on colorectal, non-small cell lung and pancreatic cancer cell lines. These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [146]
Citations
Cites
1 retracted
RETRACTED: Death-receptor activation halts clathrin-dependent endocytosis
Austin, C. D., Lawrence, D. A., Peden, A. A., Varfolomeev, E. E., Totpal, K., De Mazière, A. M., Klumperman, J., Arnott, D., Pham, V., Scheller, R. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604044103 · Cited by 112 · cited 15×
“We used the phage display approach to develop a fully human, affinity-matured IgG1/l3 monoclonal antibody (called Apomab) that triggers apoptosis upon interaction with human DR5.”
ResultSelf-citationRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887 · cited 1×
“caspase-3, -6 and -7), which drive the apoptotic cell death program.(10,11) Two principal signaling pathways control cellular caspase activation: the intrinsic pathway is initiated”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“these receptors can trigger apoptosis in various types of cancer cells, while sparing most normal cell types.(17,20) Two molecular types of proapoptotic receptor agonists (PARAs) that target”
BackgroundSelf-citation[19] Rapid and efficient site-specific mutagenesis without phenotypic selection
Kunkel, T. A., Roberts, J. D., & Zakour, R. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54085-x · Cited by 5,261
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Cited by
Items 101–152 of 152
Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure
Kuhla, A., Hauke, M., Sempert, K., Vollmar, B., & Zechner, D. (2013) · AGE · doi:10.1007/s11357-012-9506-7 · Cited by 9
“For example, binding of the antibody Apomab can cluster and thereby activate the proapoptotic receptor death receptor5 (Adams et al. 2008).”
Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy
Wang, W., He, W. Z., Wang, L., Zhang, G., & Gao, B. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.10 · Cited by 9
Targeting Apoptosis Signaling in Pancreatic Cancer
Fulda, S. (2011) · Cancers · doi:10.3390/cancers3010241 · Cited by 11
“In pancreatic carcinoma, Apomab (agonistic antibody against TRAIL-R2) was shown to be effective in pancreatic cancer as a single agent and in combination with chemotherapy [33].”
BackgroundShivange, G., Mondal, T., Lyerly, E., Bhatnagar, S., Landen, C. N., Reddy, S., Kim, J., Doan, B., Riddle, P., & Tushir‐Singh, J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109953 · Cited by 8
“Notably, despite numerous CRD1- and CRD2-tar-geting DR5 agonist antibodies, apomab is the only known (or published) CRD3 targeting DR5 agonist antibody (Adams et al., 2008).”
BackgroundInfluentialJiang, J., Liu, X., Deng, L., Zhang, P., Wang, G., Wang, S., Liu, H., & Su, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.002 · Cited by 8
“Consequently, TRAIL-based therapies aim to triggering apoptosis in cancer cells by providing the soluble TRAIL or monoclonal antibodies targeting the death receptors (Adams et al., 2008; Camidge, 2008; Forero-Torres et al., 2010; Hotte et al., 2008; Merchant et al., 2012; Wakelee et al., 2010; Younes et al., 2010).”
BackgroundIdentification and characterization of a novel agonistic anti-DR4 human monoclonal antibody
Feng, Y., Xiao, X., Zhu, Z., & Dimitrov, D. S. (2010) · mAbs · doi:10.4161/mabs.2.5.12570 · Cited by 8
Targeting a Novel N-terminal Epitope of Death Receptor 5 Triggers Tumor Cell Death
Zhang, P., Zheng, Y., Shi, J., Zhang, Y., Liu, S., Liu, Y., & Zheng, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.070680 · Cited by 7
Du, Y.-W., Chen, J., Bai, H.-L., Huang, H.-Y., Wang, J., Li, S., Liu, G., Jiang, Q., Chai, J. X., Yue-ping, Z., et al. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0827 · Cited by 9
Kang, Z., Goldstein, S. D., Yu, Y., Meltzer, P. S., Loeb, D. M., & Cao, L. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.298 · Cited by 7
“Various agonist therapeutic antibodies against death receptors exhibit anti-tumour activities in preclinical models (Adams et al, 2008; Jin et al, 2008; Luster et al, 2009; Kaplan-Lefko et al, 2010) and are in clinical development (Ashkenazi and Herbst, 2008).”
BackgroundChemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics
Masum, A., Aoki, S., Rahman, M., & Hisamatsu, Y. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00183d · Cited by 6
Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment
Carreira, B., Acúrcio, R. C., Matos, A. I., Peres, C., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Bento, M., Satchi‐Fainaro, R., & Florindo, H. F. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000147 · Cited by 7
Baudin, A., Guichard, A., Collie, G. W., Rousseau, S., Chaignepain, S., Hocquellet, A., Berbon, M., Loquet, A., Mackereth, C. D., Guichard, G., et al. (2018) · Biomolecular NMR Assignments · doi:10.1007/s12104-018-9828-1 · Cited by 5
Targeted IgMs agonize ocular targets with extended vitreal exposure
Chen, Y., Paluch, M. T., Zorn, J. A., Rajan, S., Leonard, B. C., Estevez, A., Brady, J. R., Chiu, H. H., Phung, W., Famili, A., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1818436 · Cited by 5
Proteomic tools for the characterization of cell death mechanisms in drug discovery
Anania, V. G., & Lill, J. R. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400151 · Cited by 5
Guo, L., Sun, X., Hao, Z., Huang, J., Han, X., You, Y., Li, Y., Shen, M., Ozawa, T., Kishi, H., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19918 · Cited by 4
“Over the past decade, binding of the TRAIL trimer to TRAIL-R1 and/or TRAIL-R2 has been shown to selectively induce apoptosis in tumor cells by activating extrinsic and intrinsic apoptosis pathways [11-23].”
BackgroundInfluentialClinical trials of promising apoptosis modulating drugs
Sharma, N., Kumari, R. M., Arya, G., Gupta, N., Chandra, R., & Nimesh, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815762-6.00010-x · Cited by 5
Juan, G., Zoog, S. J., & Ferbas, J. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-374912-3.00012-2 · Cited by 3
“Since activation of caspases appears to be one of the most specific markers of apoptosis, measuring activated caspase-3 after DR5 signaling constitutes a means of evaluating the pharmacodynamic effect of agonistic drugs targeting this pathway (Adams et al., 2008; Ashkenazi et al., 2008; Herbst et al., 2010; Kaplan-Lef…”
BackgroundInfluentialQiao, C., Hu, M., Guo, L., Lv, M., Zhou, L., Geng, J., Lang, X., Li, X., Li, Y., Yuan-fang Ma, A., et al. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-40 · Cited by 3
“Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, et al: Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.”
BackgroundInfluentialTargeting death receptors: is this trail still hot?
Mody, R. J. (2013) · PubMed · doi:10.3978/j.issn.2224-4336.2013.02.01 · Cited by 3
“MAbs have proven to be effective clinical cancer therapeutics because they can selectively target specific antigens and have a much longer half-life than rh-TRAIL ligands (19,20).”
BackgroundInfluentialEmerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Kaur, J., Singh, P., Enzler, T., & Sahai, V. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1905795 · Cited by 3
Implications of a newly discovered DR5 specific antagonistic peptide for neurodegenerative disorders
Heins, M., & Quax, W. J. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.4255/mcpharmacol.10.13 · Cited by 3
“Also, there have been antibodies developed that bind DR5 specifically (23).”
BackgroundRole of Leptomycin in p53 Induced Apoptosis
Ramakrishna, S. C. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000203 · Cited by 3
Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies
Bellail, A. C., Mulligan, P., & Hao, C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_41 · Cited by 2
Qiao, X., Ye, T., Wu, T., Han, X., Sun, T., Wang, H., Jia, J., Dai, Y., Yun, R., Jiang, S., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02324-z · Cited by 2
Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer
Fulda, S. (2009) · Current Signal Transduction Therapy · doi:10.2174/157436209787048676 · Cited by 1
Shim, J., Huang, A., & Miller, A. S. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.05.004 · Cited by 1
Kline, C. L. B., Wagner, J., Lulla, A. R., Ralff, M. D., Lev, A., Zhou, L., Prabhu, V. V., Stogniew, M., Schalop, L., Oster, W., et al. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527801756.ch23 · Cited by 1
Role of the Immune System in Cancer Development and Therapeutic Implications
Multhoff, G., & Astner, S. T. (2009) · Medical radiology · doi:10.1007/978-3-540-74386-6_7 · Cited by 1
Death Receptors at the Molecular Level: Therapeutic Implications
MacFarlane, M. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0021998
Ligand binding and receptor network formation in the tumor necrosis factor superfamily.
Valley, C. C. (2012) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Neumann, S. P. (2013) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-2151
Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent
Allen, J. E. (2012) · ScholarlyCommons (University of Pennsylvania)
Seifert, O. (2014) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-2326
Towards new therapeutic strategies in chondrosarcoma
Schrage, Y. M. (2009) · Leiden Repository (Leiden University)
Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies
Bellail, A. C., & Hao, C. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7070-0_11
Conformational Dynamics Associated with Signaling in Tumor Necrosis Factor Receptors
Lewis, A. K. (2015) · University of Minnesota Digital Conservancy (University of Minnesota)
Apoptose: to kill or not to kill.
Geboes, K., & Damme, N. V. (2011)
Génération et caractérisation de nouveaux anticorps anti-DR4 et anti-DR5
Dubuisson, A. (2018) · theses.fr (ABES) · doi:10.70675/18cb09d7z710ez4fc1zbf98z7f6e8a1ae220
Mechanistic Studies of Extrinsic Apoptosis by Therapeutic Molecules in Cancer Cells
Hua, Y. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Apoptosis, necroptosis, and pyroptosis in health and disease
Liao, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00008-7 · Cited by 1
Reddy, A., Growney, J. D., Wilson, N. S., Emery, C. M., Johnson, J. A., Ward, R., Monaco, K., Korn, J. M., Monahan, J. E., Stump, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146635
Stern, H. M., Padilla, M., Wagner, K., Amler, L. C., & Ashkenazi, A. (2023) · doi:10.1158/1078-0432.c.6518641
Self-citationStern, H. M., Padilla, M., Wagner, K., Amler, L. C., & Ashkenazi, A. (2023) · doi:10.1158/1078-0432.c.6518641.v1
Self-citationKang, Z., Chen, J., Yu, Y., Li, B., Sun, S., Zhang, B., & Cao, L. (2023) · doi:10.1158/1078-0432.c.6518703
TRAIL signalling regulation by ezrin
Iessi, E. (2011) · theses.fr (ABES) · doi:10.70675/93da8855zf26dz4244z82a0zadae8f48c269
Shlyakhtina, Y. (2016) · theses.fr (ABES) · doi:10.70675/8136eca9z2b12z459az8016zafc790325ed5
Études structurales de ligands peptidomimétiques de TRAIL complexés au récepteur de mort DR5
Baudin, A. (2018) · theses.fr (ABES) · doi:10.70675/84804ca7zb134z443fz9d8czcc18ce1b7d50 · Cited by 1
Galectin-9binds to trail agonist receptors and regulates trail-induced apoptosis
França, N. D. (2021) · theses.fr (ABES) · doi:10.70675/210a2663z2466z4d80zbc81z54fa518d30d4
BindingDB (2026) · UC San Diego · doi:10.7270/q2bv7nkg
Metadata
- Authors
- Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., & Ashkenazi, A.
- Affiliations
- Genentech (US)
- Corresponding author
- Ashkenazi, A
- Venue
- Cell Death & Differentiation
- Published
- 2008-01-25
- Volume
- 15
- Issue
- 4
- Pages
- 751-761
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2074106785
- Cited by
- 148
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 1 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 7 · 2013: 19 · 2012: 12
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- DR5, agonistic monoclonal antibody, antigen-antibody reaction, extrinsic apoptotic pathway, TRAIL receptors, FADD, caspase-8, receptor clustering, selective cytotoxicity, anticancer activity, colorectal cancer, non-small cell lung cancer, pancreatic cancer
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Affinity, Antibody Specificity, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Antibody, Dose-Response Relationship, Drug, Female, Humans, Mice, Nude, Models, Molecular, Neoplasms, Experimental, Protein Binding, Protein Conformation, Receptor Aggregation, Time Factors, Signal Transduction, Apoptosis, Crystallography, X-Ray, Epitope Mapping, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Caspase 8, Fas-Associated Death Domain Protein, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.